1
|
NOVACK G. Expedited regulatory product approval in the time of COVID-19. Ocul Surf 2022; 26:345-348. [PMID: 35640837 PMCID: PMC9144837 DOI: 10.1016/j.jtos.2022.05.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
|
2
|
Novack GD. Eyes on New Product Development. J Ocul Pharmacol Ther 2022; 38:201-202. [PMID: 35325572 DOI: 10.1089/jop.2022.29090.gdn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Gary D Novack
- PharmaLogic Development, Inc., San Rafael, California, USA.,Department of Ophthalmology, University of California, Davis, School of Medicine, Sacramento, California, USA
| |
Collapse
|